SurModics Down 11.1% Since SmarTrend Downtrend Call (SRDX)
Comtex SmarTrend(R) - Mon May 12, 9:58AM CDT
SmarTrend identified a Downtrend for SurModics (NASDAQ:SRDX) on March 24th, 2014 at $23.60. In approximately 2 months, SurModics has returned 11.13% as of today's recent price of $20.97.
SurModics Has Returned 13.0% Since SmarTrend Recommendation (SRDX)
Comtex SmarTrend(R) - Mon May 05, 9:14AM CDT
SmarTrend identified a Downtrend for SurModics (NASDAQ:SRDX) on March 24th, 2014 at $23.60. In approximately 1 month, SurModics has returned 12.99% as of today's recent price of $20.53.
Marginal Earnings Beat at SurModics, Sales Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 2:50PM CDT
SurModics (SRDX) reported lower-than-expected sales in the quarter.
SurModics Reports Second Quarter Fiscal 2014 Results
Business Wire - Thu May 01, 3:01PM CDT
--GAAP EPS of $0.18 Includes One-time $0.04 Non-cash Charge
SurModics to Webcast Second Quarter 2014 Earnings Conference Call on May 1
Business Wire - Tue Apr 22, 7:01AM CDT
SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its second quarter 2014 conference call on Thursday, May 1, at 4:00 p.m. CT (5:00 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
Balanced View on Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:20PM CDT
On Apr 4, we issued an updated research report on Genomic Health.
Edwards' Intuity Elite Cleared in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:10PM CDT
Edwards Lifesciences has received CE Mark approval for its Intuity Elite valve system.
New Jobs at Baxter's Malta Facility - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 5:03PM CDT
BAX is seen making efforts to meet its current and future business needs by investing in its manufacturing infrastructure and employee capabilities.
Boston Scientific Posts Encouraging CRT-TAVR Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 2:00PM CDT
Boston Scientific's shares gained 0.8% in the trading session that followed the release of the study results.
Edwards' Sapien XT Betters Medtronic Heart Valve - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 2:50PM CDT
Edwards' shares gained 6.3% in the trading session following this impressive news release.
Covidien's Ablation System: A Sure Winner - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:25PM CDT
Covidien recently announced results from its SURF clinical trial, reporting that its Barrx RF Ablation System proved effective in treating patients with Barrett's esophagus.
FDA Clears Meridian's B. Pertussis Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:40PM CDT
Meridien's Illumigene Pertussis is superior to conventional Bordetella pertussis bacterial culture.
Updated Research Report on Edwards - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 2:00PM CDT
On Apr 01, we issued an updated research report on Edwards Lifesciences Corporation.
Covidien Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:10PM CDT
Covidien posted strong fiscal first-quarter results recording year-over-year increases both in revenues and adjusted earnings.
Perrigo Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 5:30PM CDT
Perrigo inked a deal to manufacture store brand versions of nutritional drinks for adults.
Baxter Downgraded to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 11:10AM CDT
Baxter's operating margin dropped 280 basis points (bps) year over year to 21% in the quarter.
St. Jude Medical's Prodigy Neurostimulator Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 3:00PM CDT
St. Jude Medical's Prodigy Chronic Pain System is based on neurostimulation therapy in addition to Burst Technology.
Stryker Raised to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 2:00PM CDT
A dividend increment of 15% as declared by the board of directors of Stryker last month reflects the company's strong financial position and earnings strength.
Symmetry Medical Sheds Light on UK Plant Fire - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 5:24PM CDT
Symmetry's shares, which are down around 7% over a year, gained 3.4% yesterday to close at $10.23.
Q4 Loss Widens at Amedisys - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:00AM CDT
Amedisys recorded adjusted loss from continuing operations per share of 5 cents in the fourth quarter of 2013.